New tracers beyond FDG in head and neck oncology

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 5, 2011, Pages 529-540

  Gornik, G ^a   Weber, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Head and neck neoplasms; Molecular imaging; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 FLUORO 3' DEOXYTHYMIDINE F 18; AMINO ACID; CALCIUM CHANNEL L TYPE; CARBON 14; CD44V6 ANTIGEN; CD98 ANTIGEN; CUPRIC ION; DIACETYL 2,3 BIS(N 4 METHYL 3 THIOSEMICARBAZONATO); FLUORODEOXYGLUCOSE; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETHYL TYROSINE F 18; FLUOROMETHYL TYROSINE F 18; LEUCINE; METHIONINE C 11; MONOCLONAL ANTIBODY U36 ZR 89; RADIOPHARMACEUTICAL AGENT; TRACER; TRITIUM; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID TRANSPORT; ANGIOGENESIS; ANTIGEN EXPRESSION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELL ACTIVATION; CELL PROLIFERATION; DISTANT METASTASIS; DRUG UPTAKE; EMISSION TOMOGRAPHY; ENDOTHELIUM CELL; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE DISPLAY; IMMUNO POSITRON EMISSION TOMOGRAPHY; INFLAMMATORY CELL; ISOTOPE LABELING; MOLECULAR IMAGING; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR DIAGNOSIS;

AMINO ACIDS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84856189350     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Colella G, Tozzi U, Pagliarulo V, Bove P. Warthin tumor: a potential source of diagnostic error. J Craniofac Surg;21:1978-81.
2. Lang BH, Law TT. The Role of 18F-Fluorodeoxyglucose Posi-tron Emission Tomography in Thyroid Neoplasms. Oncologist 2011;16:458-66.
3. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol 2008;97:649-52. (Pubitemid 351812964)
4. Burrell SC, Van den Abbeele AD. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants. Mol Imaging Biol 2005;7:244-56. (Pubitemid 41348867)
5. Isselbacher KJ. Sugar and amino acid transport by cells in culture - differences between normal and malignant cells. N Engl J Med 1972;86:929-33.
6. McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994;299(Pt 2):321-34. (Pubitemid 24114121)
7. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med Jun 2008;49 Suppl 2:43S-63S. (Pubitemid 351948036)
8. Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R, Bertran J. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem 2005;280:12002-11. (Pubitemid 40418518)
9. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-94.
10. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995;36:484-92.
11. Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Krüger A et al. O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002;29:1039-46.
12. Suzuki M, Yamaguchi K, Honda G, Iwata R, Furumoto S, Jeong MG et al. An experimental study on O-[18F]fluoromethyl-L-tyrosine for differentiation between tumor and inflammatory tissues. Ann Nucl Med 2005;19:589-95. (Pubitemid 43161844)
13. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H. Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 1992;33:691-5.
14. Lindholm P, Leskinen S, Lapela M. Carbon-11-methionine uptake in squamous cell head and neck cancer. J Nucl Med 1998;39:1393-7. (Pubitemid 28373564)
15. Wedman J, Pruim J, Langendijk JA, van der Laan BF. Visualization of small glottic laryngeal cancer using methyl-labeled 11C-methionine positron emission tomography. Oral Oncol 2009;45:703-5.
16. Geets X, Daisne JF, Gregoire V, Hamoir M, Lonneux M. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol 2004;71:267-73. (Pubitemid 38686663)
17. Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A et al. Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. J Nucl Med 2003;44:526-32. (Pubitemid 39663419)
18. Lindholm P, Leskinen-Kallio S, Grénman R, Lehikoinen P, Någren K, Teräs M et al. Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and [HC] methionine. Int J Radiat Oncol Biol Phys 1995;32:787-94.
19. Nuutinen J, Jyrkkio S, Lehikoinen P, Lindholm P, Minn H. Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography. Radiother Oncol 1999;52:225-32. (Pubitemid 29486641)
20. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205-12. (Pubitemid 29044193)
21. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9. (Pubitemid 30262620)
22. Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374-80. (Pubitemid 44630797)
23. Pauleit D, Stoffels G, Schaden W, Hamacher K, Bauer D, Tellmann L et al. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. J Nucl Med 2005;46:411-6. (Pubitemid 43093148)
24. Balogova S, Perie S, Kerrou K, Grahek D, Montravers F, Angelard B et al. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. Mol Imaging Biol 2008;10:364-73.
25. Haerle SK, Fischer DR, Schmid DT, Ahmad N, Huber GF, Buck A. (18)F-FET PET/CT in Advanced Head and Neck Squamous Cell Carcinoma: an Intra-individual Comparison with (18)F-FDG PET/CT. Mol Imaging Biol 2011;13:1036-42.
26. Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K et al. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007;21:129-35. (Pubitemid 46495613)
27. Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O'Sullivan F et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging 2002;1:145-50.
28. Wells JM, Mankoff DA, Muzi M, O'Sullivan F, Eary JF, Spence AM et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Mol Imaging 2002;1:151-9.
29. Mankoff DA, Shields AF, Link JM, Graham MM, Muzi M, Peterson LM et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med 1999;40:614-24. (Pubitemid 29171803)
30. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998;4:1334-6. (Pubitemid 28512118)
31. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7. (Pubitemid 34988769)
32. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoroL-thymidine: a comprehensive evaluation. Nucl Med Commun 2009;30:908-17.
33. Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer AJ, Hoekstra HJ et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med 2004;45:226-31. (Pubitemid 47618641)
34. Linecker A, Kermer C, Sulzbacher I, Angelberger P, Kletter K, Dudczak R et al. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 2008;47:80-5; quiz N12.
35. Hoshikawa H, Nishiyama Y, Kishino T, Yamamoto Y, Haba R, Mori N. Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol Imaging Biol 2011;13:172-7.
36. Troost EG, Vogel WV, Merkx MA, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007;48:726-35. (Pubitemid 47604972)
37. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med;51:866-74.
38. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK et al. Kinetic analysis of 3′-deoxy-3′-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med 2009;50:1028-35.
39. de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ et al. Reproducibility of quantitative 18F-3′-deoxy-3′- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009;36:389-95.
40. Been LB, Hoekstra HJ, Suurmeijer AJ, Jager PL, van der Laan BF, Elsinga PH. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol 2009;45:e211-215.
41. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9. (Pubitemid 27318643)
42. Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C, Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998;42:35-41. (Pubitemid 28435593)
43. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol Oct;77:18-24.
44. Barendsen GW, Koot CJ, Van Kersen GR, Bewley DK, Field SB, Parnell CJ. The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol Relat Stud Phys Chem Med 1966;10:317-27.
45. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and Radiation Response in Human Tumors. Semin Radiat Oncol 1996;6:3-9. (Pubitemid 26029370)
46. Gabalski EC, Adam M, Pinto H, Brown JM, Bloch DA, Terris DJ. Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers. Laryngoscope 1998;108:1856-60. (Pubitemid 28559672)
47. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757. (Pubitemid 44832019)
48. Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol 2008;35:236-50. (Pubitemid 351787693)
49. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69.541-51.
50. Lambin P, Petit SF, Aerts HJ, van Elmpt WJ, Oberije CJ, Starmans MH et al. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol 2010;96:145-52.
51. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60. (Pubitemid 30317470)
52. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104. (Pubitemid 46622121)
53. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37. (Pubitemid 35446742)
54. Kaanders JH, Pop LA, Marres HA, Bruaset I, van den Hoogen FJ, Merkx MA et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:769-78. (Pubitemid 34158740)
55. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
56. Schoder H, Ong SC. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med 2008;38:119-28. (Pubitemid 351163199)
57. Heuveling DA, de Bree R, van Dongen GA. The potential role of non-FDG-PET in the management of head and neck cancer. Oral Oncol 2010;47:2-7.
58. Krohn KA, Link JM, Mason Rl5. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S-148S. (Pubitemid 351948041)
59. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005;32:1384-91. (Pubitemid 41746841)
60. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41. (Pubitemid 44497258)
61. Nehmeh SA, Lee NY, Schroder H, Schröder H, Squire O, Zanzonico PB, Erdi YE et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42. (Pubitemid 350251048)
62. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol 2009;54:3083-99.
63. Gronroos T, Bentzen L, Marjamäki P, Murata R, Horsman MR, Keiding S et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-20. (Pubitemid 38461566)
64. Gronroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001;42:1397-404. (Pubitemid 32852618)
65. Li L, Hu M, Zhu H, Zhao W, Yang G, Yu J. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer 2010;11:335-40.
66. Mahy P, Geets X, Lonneux M, Levêque P, Christian N, De Bast M et al. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008;35:1282-9.
67. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.
68. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13. (Pubitemid 43086004)
69. Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 2008;70:1202-12. (Pubitemid 351296127)
70. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009;36:1565-73.
71. Souvatzoglou M, Grosu AL, Roper B, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. Oct 2007;34(10):1566-1575. (Pubitemid 47476913)
72. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA - first small animal PET results. J Pharm Pharm Sci 2007;10:203-11.
73. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317-26. (Pubitemid 36556247)
74. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging 2009;53:193-200.
75. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M et al. Assessment of tumor hypoxia by (62)Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011;25:339-45
76. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
77. Verel I, Visser GW, van Dongen GA. The promise of immunoPET in radioimmunotherapy. J Nucl Med 2005;46 Suppl 1:164S-171S.
78. Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 1 2006;12(7 Pt 1):2133-40.
79. Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-90. (Pubitemid 24146794)
80. de Bree R, Roos JC, Verel I, van Dongen GA, Snow GB. Radioimmunodiagnosis of lymph node metastases in head and neck cancer. Oral Dis 2003;9:241-8. (Pubitemid 37047632)
81. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123-31.
82. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90) Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898-906. (Pubitemid 46196653)
83. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 102:117-21.
84. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H et al. In vivo VEGF imaging with radiolabeled bevaeizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313-9. (Pubitemid 47242797)
85. Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008;35:1857-67.
86. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.
87. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333-41. (Pubitemid 43733484)
88. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci. 1998;54:541-8. (Pubitemid 28325627)
89. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13(22 Pt 1):6610-6. (Pubitemid 350206795)
90. Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50 Suppl 1:74S-88S.
91. Dumont R, Deininger F, Haubner R, Maecke H, Weber W, Fani M. Novel 64Cu- and 68Ga-labeled RGD Conjugates Show Improved PET Imaging of ανβ3 Integrin Expression and Facile Radiosynthesis. J Nucl Med [In press].
92. Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss MO et al. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 2006;47:256-61. (Pubitemid 46780890)